{"entity":{"id":"trusight-oncology-500","kind":"drug","name":"TruSight Oncology 500","aka":["Illumina TruSight Oncology 500","TSO 500","TruSight Oncology 500 v2"],"tldr":"Illumina's kit that lets a hospital or research laboratory run a large cancer gene panel itself instead of sending the sample away.","summary":"TruSight Oncology 500 is Illumina's comprehensive genomic profiling kit. Version 2 sequences DNA from 523 genes and RNA from 55 genes from formalin-fixed tissue, detecting single-nucleotide variants, copy number changes, insertions and deletions, fusions and large BRCA1/2 rearrangements, and reports microsatellite instability and tumour mutational burden, in 3 to 4 days from sample to result. Homologous recombination deficiency analysis, a genomic instability score combining loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions powered by Myriad Genetics, is built into the workflow and licensed separately. A ctDNA version analyses plasma with similar DNA content. The kit is for research use only and not for diagnostic procedures; Illumina's FDA-approved diagnostic panel is TruSight Oncology Comprehensive.","status":"established","asOf":"2026-11-03","links":[{"label":"Illumina: TruSight Oncology 500 v2","url":"https://www.illumina.com/products/by-type/clinical-research-products/trusight-oncology-500.html"}],"tags":["test"],"related":["trusight-oncology-comprehensive","msi-high","tmb-high"],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":["illumina"],"institutions":[],"pathways":[],"terms":["ngs","tmb","msi","hrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: results from this kit come from the laboratory that ran it, under that laboratory's own validation; the FDA-approved companion diagnostic claims belong to TruSight Oncology Comprehensive."],"brand":"TruSight Oncology 500","modality":"Comprehensive genomic profiling test kit run by laboratories (NGS, research use only)","mechanism":"A hybrid-capture kit that a laboratory runs on its own Illumina sequencer: DNA from 523 genes and RNA from 55 genes, with tumour mutational burden, microsatellite instability and an optional homologous recombination deficiency score.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/trusight-oncology-500/","neighbours":{"drug":[{"id":"trusight-oncology-comprehensive","kind":"drug","name":"TruSight Oncology Comprehensive","route":"/drugs/trusight-oncology-comprehensive/"}],"biomarker":[{"id":"msi-high","kind":"biomarker","name":"MSI-high (microsatellite instability by PCR or sequencing)","route":"/biomarkers/msi-high/"},{"id":"tmb-high","kind":"biomarker","name":"TMB-high (tumour mutational burden >= 10 mutations per megabase)","route":"/biomarkers/tmb-high/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"}],"company":[{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/"}],"term":[{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/"},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/"}]}}